Compare Anheuser-Busch Inbev SA (BUD) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Centene Corp — how do they compare? Anheuser-Busch Inbev SA trades at $80.61 (market cap $163.79B), while Centene Corp trades at $65.66 (market cap $32.89B). The key difference: Anheuser-Busch Inbev SA is far larger — about 5× Centene Corp's market cap, and Anheuser-Busch Inbev SA pays a 1.62% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| BUD | CNC | |
|---|---|---|
Market Cap | $163.79B | $32.89B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $68.72 |
52-Week Low | $57.93 | $26.17 |
Enterprise Value | $228.20B | $21.93B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.76, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $90.17. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 expected, while revenue trends show modest growth, and net income margin improved to 11.52% in 2025. Cash flow remains positive, and debt-to-asset ratios have declined steadily since 2021.
The outlook is positive given strong analyst buy ratings (57.78%) and projected earnings growth, but risks include competitive pressures and macroeconomic sensitivity. The stock offers value with a P/E of 18.05 and stable profitability, though investor sentiment is mixed amid recent institutional selling and news of a major shareholder divestment.
Centene (CNC) trades at $65.77, up 2.48% with a bullish technical signal. Recent Q2 2026 earnings beat expectations with EPS of $2.51 versus $1.09 estimate, driven by margin recovery and cost control. Revenue grew to $194.78B in 2025, though net income was negative at -$6.67B. Valuation ratios are attractive with P/E of 8.06 and P/S of 0.16. Analyst consensus is strongly bullish with 61.37% buy ratings and a $70.36 price target.
Outlook is positive due to raised 2026 guidance and operational improvements, but risks include Medicaid membership softness and persistent negative margins. The stock offers value potential if profitability rebounds as projected, though investors should monitor medical cost trends and regulatory changes affecting government healthcare programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
